How do you think the new GigE standards will influence the machine vision industry?
Respond or ask your question now!
Swissray has received from Frost & Sullivan the "Best Product Value" award for their market leading digital radiography systems. This new technology provides high quality medical radiographic images in seconds at a significantly lower cost than conventional or computed radiography because,among other factors, film, imaging plates, cassettes and chemical processing are not required. By utilizing a multifunctional single detector design, Swissray offers an affordable high quality solution for direct digital radiography. Swissray currently provides a full range of DR systems for orthopedic applications, imaging centers, hospitals and emergency departments.All of Swissray's DR systems include fully automated, remote controlled system positioning. Swissray offers customers choice between their unique 16 bit QuadCCD and their amorphous silicon flat panel detector technologies.
Trixell is a joint-venture company committed to the development and production of a complete family of X-ray flat panel digital detectors for the entire radiological imaging industry. Its three parent companies, Thales Electron Devices 51%, Philips Medical Systems 24.5% and Siemens Medical Solutions 24.5% bring complementary skills to Trixell with the common goal of meeting the complete range of X-ray detection requirements for this demanding market. Thales Electron Devices is the world's leading maker of X-ray image intensifiers and radiological imaging devices, providing comprehensive expertise in detection technology. The commitment and the support of its parent companies are key advantages for long-term development of Trixell.
For more information about Swissray's family of ddR solutions, visit theSwissray website at http://www.swissray.com
Disclaimer: Swissray's common stock is quoted on the Pink Sheets. The Pink Sheets does not require companies whose securities are quoted upon its systems to meet any listing requirements. With the exception of a few foreign issuers, the companies quoted in the Pink Sheets tend to be closely held, extremely small and/or thinly traded. Most do not meet the minimum listing requirements for trading on a national securities exchange, such as the NewYork Stock Exchange or the NASDAQ Stock Market. Many of these companies (including Swissray) do not file periodic reports or audited financial statements with the Securities and Exchange Commission, making it very difficult for investors to find reliable, unbiased information about those companies. For all of these reasons, companies quoted in the Pink Sheets can be among the most risky investments. That's why you should take extra care to thoroughly research any company quoted exclusively in the Pink Sheets. Beaware that some broker-dealers are required by SEC Rule 15c2-11 to have some information about the issuer. Ask your broker-dealer whether it has any Rule 15c2-11 information before you invest. Swissray does not undertake any obligation to update the information contained in this press release beyond the published date.
Safe Harbor: This press release may contain forward-looking statements,and as such, may involve risks and uncertainties. Forward-looking statements, which are based on certain assumptions and describe future plans, strategies,and expectations, are generally identifiable by the use of words such as "believe," "expect," "intend," "anticipate," "estimate," "project," or similar expressions. Swissray's actual results, performance, actions and achievements may differ materially from the results, performance, actions and achievements expressed or implied in such forward-looking statements. Under the Private Securities Litigation Reform Act of 1995 Investors are cautioned that certain statements contained in this document as well as some statements in periodic press releases and some oral statements of Swissray officials during presentations about Swissray, are "forward- looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act").